Sun Pharma's ILUMYA Receives FDA Review for Psoriatic Arthritis Treatment Expansion

Sun Pharmaceutical Industries Limited recently made a significant announcement regarding its product ILUMYA® (tildrakizumab-asmn). The United States Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for ILUMYA, aimed at treating adults with active psoriatic arthritis. This pivotal news supports Sun Pharma's commitment to addressing the needs of patients dealing with psoriatic disease. The FDA's decision is expected by October 29, 2026.

The landscape of treatments for active psoriatic arthritis could change significantly if ILUMYA gains approval. As noted by Rick Ascroft, CEO of Sun Pharma North America, joint symptoms often exacerbate the burden on those living with this condition. The aspiration behind ILUMYA is for it to become a leading advanced systemic treatment for psoriatic arthritis, distinguished by its status as the only healthcare professional-administered IL-23 biologic.

ILUMYA initially gained FDA approval in 2018 for the treatment of adults suffering from moderate-to-severe plaque psoriasis, specifically aimed at patients eligible for systemic therapy or phototherapy. Since then, the drug's indications have expanded, with approvals for treating scalp and nail plaque psoriasis received in April 2024 and December 2025, respectively. To date, ILUMYA has also obtained marketing authorization from over 55 international health authorities, affirming its global reach and trust within the medical community.

Through its established use, ILUMYA has positively impacted nearly 140,000 patients worldwide, offering durable skin clearance and ensuring a safety profile characterized by extensive clinical follow-up. Moreover, real-world evidence suggests strong adherence among patients, allowing many to stay on treatment longer. Dermatologists both in the US and worldwide have widely endorsed ILUMYA as a reliable and effective treatment option for adults with moderate-to-severe plaque psoriasis.

The sBLA for ILUMYA in treating psoriatic arthritis is grounded in the positive results garnered from the Phase 3 clinical trials known as INSPIRE-1 and INSPIRE-2. These trials were conducted to evaluate the efficacy and safety of tildrakizumab in adults with active psoriatic arthritis, with promising top-line findings reported in July 2025. Full data and study details are expected to be revealed at upcoming medical conferences.

Despite its potential, ILUMYA does come with considerations for its use. Serious side effects can occur, including severe allergic reactions, and patients must be informed to avoid it if they have a known allergy to the drug. Furthermore, ILUMYA can increase the risk of infections, warranting careful pre-treatment evaluation for tuberculosis and other active infections. Medical professionals are advised to monitor for any signs of serious infections during and after treatment.

Psoriatic arthritis itself is a chronic condition that reflects an abnormal response from the immune system, leading to joint swelling, pain, and stiffness. It can develop at any point in life and may be present in individuals irrespective of the severity of their psoriasis, affecting nearly one in three psoriasis patients. Estimates suggest that 2.4 million Americans live with psoriatic arthritis, with a significant portion potentially undiagnosed.

In summary, if approved, ILUMYA’s application for psoriatic arthritis would signify a meaningful extension of treatment options for patients suffering from this debilitating disease, reinforcing Sun Pharma's dedication to improving patient care aimed at better managing psoriatic disease. The healthcare community eagerly awaits the FDA's final decision, hopeful for expanded therapeutic avenues to help those affected.